Clinical Trial Detail

NCT ID NCT02464657
Title Nivolumab in Acute Myeloid Leukemia (AML)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

bone marrow cancer

Therapies

Dexamethasone

Cytarabine + Idarubicin + Nivolumab

Age Groups: adult

No variant requirements are available.